Clinical Trial Update: A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

ClinicalTrials.gov entry indicates that HRS-5041-103 is a Phase 1 study assessing safety, tolerability, pharmacokinetics and efficacy in metastatic castration-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HRS-5041

Snippet

Sponsor: Atridia Pty Ltd. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1 | Status: RECRUITING